{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:40Z","timestamp":1792787980408,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["No.JCYJ20210324114600002"],"award-info":[{"award-number":["No.JCYJ20210324114600002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["No.JCYJ20210324114600002"],"award-info":[{"award-number":["No.JCYJ20210324114600002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["No.JCYJ20210324114600002"],"award-info":[{"award-number":["No.JCYJ20210324114600002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["No.JCYJ20210324114600002"],"award-info":[{"award-number":["No.JCYJ20210324114600002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["No.JCYJ20210324114600002"],"award-info":[{"award-number":["No.JCYJ20210324114600002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["No.JCYJ20210324114600002"],"award-info":[{"award-number":["No.JCYJ20210324114600002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cultivation Program of Independent Innovation Achievements for Graduate Students of Shenzhen University"},{"name":"Shenzhen Key Laboratory for cancer metastasis and personalized therapy","award":["No.ZDSYS20210623091811035"],"award-info":[{"award-number":["No.ZDSYS20210623091811035"]}]},{"name":"Shenzhen Key Laboratory for cancer metastasis and personalized therapy","award":["No.ZDSYS20210623091811035"],"award-info":[{"award-number":["No.ZDSYS20210623091811035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13595-1","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:35:47Z","timestamp":1738740947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Construction and evaluation of a prognostic model for cervical cancer based on dynamic hematological and clinical features"],"prefix":"10.1186","volume":"25","author":[{"given":"Huangrong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"1","key":"13595_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"9077","key":"13595_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(97)02250-2","volume":"350","author":"F Landoni","year":"1997","unstructured":"Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535\u201340.","journal-title":"Lancet"},{"key":"13595_CR3","unstructured":"National Comprehensive Cancer Network. The NCCN cervical cancer clinical practice guidelines in oncology (version 1.2025). Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1426."},{"issue":"9","key":"13595_CR4","doi-asserted-by":"publisher","first-page":"e1363","DOI":"10.1634\/theoncologist.2019-0902","volume":"25","author":"D Isla-Ortiz","year":"2020","unstructured":"Isla-Ortiz D, Palomares-Castillo E, Mille-Loera JE, Ramirez-Calderon N, Mohar-Betancourt A, Meneses-Garcia AA, et al. Cervical cancer in young women: do they have a worse prognosis? A retrospective cohort analysis in a population of Mexico. Oncologist. 2020;25(9):e1363-71.","journal-title":"Oncologist"},{"issue":"1","key":"13595_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ygyno.2021.01.034","volume":"161","author":"L Varela Cagetti","year":"2021","unstructured":"Varela Cagetti L, Gonzague-Casabianca L, Zemmour C, Lambaudie E, Houvenaeghel G, Provansal M, et al. The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer. Gynecol Oncol. 2021;161(1):166\u201372.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"13595_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jso.20329","volume":"91","author":"SR Walsh","year":"2005","unstructured":"Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181\u20134.","journal-title":"J Surg Oncol"},{"issue":"12","key":"13595_CR7","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1111\/cas.15964","volume":"114","author":"Q Huai","year":"2023","unstructured":"Huai Q, Luo C, Song P, Bie F, Bai G, Li Y, et al. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy. Cancer Sci. 2023;114(12):4484\u201398.","journal-title":"Cancer Sci"},{"issue":"5","key":"13595_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177137","volume":"12","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS One. 2017;12(5): e0177137.","journal-title":"PLoS One"},{"issue":"12","key":"13595_CR9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1515\/cclm-2015-1191","volume":"54","author":"BL Wang","year":"2016","unstructured":"Wang BL, Tian L, Gao XH, Ma XL, Wu J, Zhang CY, et al. Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. Clin Chem Lab Med. 2016;54(12):1963\u20139.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"13595_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","volume":"61","author":"CA Dumitru","year":"2012","unstructured":"Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61(8):1155\u201367.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"13595_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-021-07890-w","volume":"21","author":"E Yang","year":"2021","unstructured":"Yang E, Huang S, Ran X, Huang Y, Li Z. The 5-year overall survival of cervical cancer in stage IIIC-r was little different to stage I and II: a retrospective analysis from a single center. BMC Cancer. 2021;21(1):203.","journal-title":"BMC Cancer"},{"key":"13595_CR12","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.2147\/CMAR.S204154","volume":"11","author":"DD Yan","year":"2019","unstructured":"Yan DD, Tang Q, Tu YQ, Chen JH, Lv XJ. A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p. Cancer Manag Res. 2019;11:4223\u201330.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"13595_CR13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/cancers12061552","volume":"12","author":"L Pedone Anchora","year":"2020","unstructured":"Pedone Anchora L, Carbone V, Gallotta V, Fanfani F, Cosentino F, Turco LC, et al. Should the number of metastatic pelvic lymph nodes be integrated into the 2018 Figo staging classification of early stage cervical cancer? Cancers (Basel). 2020;12(6):1552.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"13595_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290905","volume":"18","author":"S Wang","year":"2023","unstructured":"Wang S, Wang Y, Zhuang J, Wu Y, Shi W, Wang L. Prognostic significance of index (LANR) composed of preoperative lymphocytes, albumin, and neutrophils in patients with stage IB-IIA cervical cancer. PLoS One. 2023;18(9): e0290905.","journal-title":"PLoS One"},{"issue":"5","key":"13595_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10147-015-0807-6","volume":"20","author":"M Mizunuma","year":"2015","unstructured":"Mizunuma M, Yokoyama Y, Futagami M, Aoki M, Takai Y, Mizunuma H. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer. Int J Clin Oncol. 2015;20(5):989\u201396.","journal-title":"Int J Clin Oncol"},{"key":"13595_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.cca.2020.09.008","volume":"510","author":"H Trinh","year":"2020","unstructured":"Trinh H, Dzul SP, Hyder J, Jang H, Kim S, Flowers J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). Clin Chim Acta. 2020;510:711\u20136.","journal-title":"Clin Chim Acta"},{"key":"13595_CR17","first-page":"100578","volume":"39","author":"O Gjyshi","year":"2023","unstructured":"Gjyshi O, Grippin A, Andring L, Jhingran A, Lin LL, Bronk J, et al. Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer. Clin Transl Radiat Oncol. 2023;39:100578.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"37","key":"13595_CR18","doi-asserted-by":"publisher","first-page":"18584","DOI":"10.1073\/pnas.1901562116","volume":"116","author":"AJ Wisdom","year":"2019","unstructured":"Wisdom AJ, Hong CS, Lin AJ, Xiang Y, Cooper DE, Zhang J, et al. Neutrophils promote tumor resistance to radiation therapy. Proc Natl Acad Sci U S A. 2019;116(37):18584\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"13595_CR19","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.ejca.2009.01.023","volume":"45","author":"S Teramukai","year":"2009","unstructured":"Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45(11):1950\u20138.","journal-title":"Eur J Cancer"},{"issue":"1","key":"13595_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2011.03.037","volume":"122","author":"S Mabuchi","year":"2011","unstructured":"Mabuchi S, Matsumoto Y, Isohashi F, Yoshioka Y, Ohashi H, Morii E, et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol. 2011;122(1):25\u201332.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"13595_CR21","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.3390\/diagnostics12102446","volume":"12","author":"X Xia","year":"2022","unstructured":"Xia X, Li D, Du W, Wang Y, Nie S, Tan Q, et al. Radiomics based on nomogram predict pelvic lymphnode metastasis in early-stage cervical cancer. Diagnostics (Basel). 2022;12(10):2446.","journal-title":"Diagnostics (Basel)"},{"key":"13595_CR22","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.2147\/JIR.S435366","volume":"16","author":"H Guo","year":"2023","unstructured":"Guo H, Feng S, Li Z, Yin Y, Lin X, Yuan L, et al. Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy. J Inflamm Res. 2023;16:5145\u201356.","journal-title":"J Inflamm Res"},{"key":"13595_CR23","doi-asserted-by":"publisher","first-page":"961678","DOI":"10.3389\/fonc.2022.961678","volume":"12","author":"K Jiang","year":"2022","unstructured":"Jiang K, Ai Y, Li Y, Jia L. Nomogram models for the prognosis of cervical cancer: a SEER-based study. Front Oncol. 2022;12:961678.","journal-title":"Front Oncol"},{"issue":"1","key":"13595_CR24","doi-asserted-by":"publisher","first-page":"13299","DOI":"10.1038\/s41598-023-39764-5","volume":"13","author":"W Chen","year":"2023","unstructured":"Chen W, Xia X, Xie X, Wei Y, Wu R, Cai W, et al. Nomogram for prognosis of elderly patients with cervical cancer who receive combined radiotherapy. Sci Rep. 2023;13(1):13299.","journal-title":"Sci Rep"},{"issue":"36","key":"13595_CR25","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","volume":"41","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. First-line pembrolizumab\u2009+\u2009chemotherapy versus placebo\u2009+\u2009chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol. 2023;41(36):5505\u201311.","journal-title":"J Clin Oncol"},{"issue":"10421","key":"13595_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","volume":"403","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Gladieff L, Martinez-Garcia J, Villacampa G, Takekuma M, De Giorgi U, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31\u201343.","journal-title":"Lancet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13595-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:35:56Z","timestamp":1738740956000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13595"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13595-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The formulation of the experimental protocol complies with the ethical guidelines of the Helsinki Declaration and has been approved by the Medical Ethics Committee of The University of Hong Kong - Shenzhen Hospital\u00a0([2022]020). Individual consent from each patient for this retrospective analysis was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}